(RTTNews) - Medical device company Insulet Corp. announced a medical device correction for its Omnipod 5 Automated Insulin Delivery System. The decision is due to an issue with the Omnipod 5 ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), today announced a Medical Device Correction for the Omnipod® 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 ...

Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.

Insulet PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. Yet, its heavy reliance on the Omnipod System and a ...

Insulet's Q2 revenue of $488M exceeded estimates, driven by strong Omnipod 5 demand and international growth. Insulet raised its full-year revenue forecast to 18%-21% growth, up from the previous ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...